- Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.
- The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being further evaluated for clinical potential in six solid tumor indications.
- The company has leveraged RADR®, a proprietary AI platform for oncology drug development, for target selection and molecular payload characterization in ADCs, and a unique, controlled conjugation approach for maximizing drug-to-antibody ratios while controlling for non-specific conjugation.
- Lantern expects to move towards IND development of the ADC program during 2024 with a focus on select solid tumors that are unresponsive or refractory to current therapies.
- ADCs are a promising and emerging class of cancer therapy that are expected to generate over $24 billion in revenue by 2030 and have been the focus of several recent M&A transactions among emerging biotech companies and global pharmaceutical companies.
Doximity Stock Jumps 10% On Q4 Earnings: What You Need To Know
Doximity's fourth-quarter revenue increased 6% year-over-year to $118.1 million, which beat the consensus estimate of $116.4 million, according to Benzinga Pro. The company reported adjusted earnings of 25 cents per share, beating analyst estimates of 20 cents per share.
